The funds will support a Phase 2B randomized controlled trial (RCT) evaluating the efficacy of SDT in patients with newly diagnosed glioblastoma (GBM).
Company Description
Alpheus Medical is a private, clinical-stage oncology company pioneering sonodynamic therapy (SDT) for the treatment of solid body cancers. The company is developing a non-invasive treatment utilizing a proprietary platform that combines Low-Intensity Diffuse Ultrasound (LIDU™) with oral 5-aminolevulinic acid (5-ALA) to selectively target and destroy cancer cells while sparing healthy tissue.